Knights of Columbus Asset Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-79,553	Closed	-$1.4M	–	339
2021 Q3	$1.4M	Buy	79,553 +575	+0.7%	+$6.72K	0.13%	216
2021 Q2	$766K	Buy	78,978 +275	+0.3%	+$2.59K	0.07%	233
2021 Q1	$845K	Buy	+78,703	New	+$973K	0.08%	251

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Knights of Columbus Asset Advisors's TRIL Position: Q4 2021 in Review

Knights of Columbus Asset Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 79,553 shares — an estimated $1.4M sold.

Knights of Columbus Asset Advisors first reported a position in TRIL in Q1 2021 and held it in 3 quarters. The position peaked at $1.4M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Knights of Columbus Asset Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Knights of Columbus Asset Advisors sold 79,553 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $1.4M.
Knights of Columbus Asset Advisors first reported a position in Trillium Therapeutics Inc. in Q1 2021 and held it in 3 quarters.
Knights of Columbus Asset Advisors's Trillium Therapeutics Inc. position peaked at $1.4M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Knights of Columbus Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.